Business Context and Reporting Period
This Form 8-K Current Report, dated July 28, 2025, details the formalization of an employment agreement between Immunovant, Inc. (IMVT) and Eric Venker, M.D., Pharm.D., who serves as the Company's Chief Executive Officer. The agreement, dated July 28, 2025, supersedes previous disclosures regarding his appointment effective April 21, 2025.
Key Financial Metrics and Compensation Structure
The filing outlines the specific compensatory arrangements for the CEO but does not report company-wide financial metrics such as revenue, profit, or cash flow.
- Base Salary: $672,000 annually.
- Target Bonus: 72.25% of base salary (approximately $485,520), subject to performance assessment.
- Equity Awards (Granted July 28, 2025):
- 1,300,000 common stock options (Unit Option Award).
- 189,900 common stock options with an aggregate grant date value of $2,250,000 (Dollar Option Award).
- 1,475,000 capped value appreciation rights (CVARs).
- CVAR Terms: Vesting requires service, clinical performance milestones, and a stock price "knock-in" of $16.76. Payout is capped at $16.76 per share with a hurdle price of $14.46.
Material Changes and Vesting Conditions
The primary material change is the formalization of the CEO's compensation package. Key vesting and holding conditions include:
- Option Vesting: 25% vests on April 21, 2026, with the remainder vesting quarterly over four years. A two-year holding period applies to shares underlying the Unit Option Award post-vesting.
- CVAR Vesting: 25% service-vests on April 1, 2026, with the remainder vesting quarterly. Full vesting is contingent on the stock price reaching $16.76.
- Change in Control: Option Awards accelerate and vest in full immediately upon a change in control.
Outlook, Risks, and Severance Provisions
The filing details significant severance protections for the CEO, which represent a contingent liability for the Company:
- Severance Triggers: Termination without Cause or resignation for Good Reason.
- Severance Package: 12 months of base salary, 12 months of target bonus, and 12 months of COBRA premium reimbursement.
- Exclusion: Severance benefits are forfeited if Dr. Venker continues employment with Roivant Sciences, Inc. following termination from Immunovant.
- Risk Factors: The CVAR award structure ties executive compensation to specific stock price thresholds ($16.76) and clinical milestones, creating variable compensation outcomes based on market and operational performance.
Investor Verification Checklist
- Verify the current trading price of IMVT relative to the $16.76 CVAR knock-in price and $14.46 hurdle price.
- Review the upcoming 10-Q for the quarter ended June 30, 2025, for the full text of the employment agreement.
- Monitor clinical development progress to assess the likelihood of satisfying the CVAR Performance Requirement.
- Confirm the total number of shares authorized under the 2019 Equity Incentive Plan to assess dilution impact from the new awards.